Identification

Name
Fluticasone furoate
Accession Number
DB08906
Type
Small Molecule
Groups
Approved
Description

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Despite the similarity in the names, fluticasone furoate and fluticasone propionate are different drugs with different properties. It is marketed under the brand name, Veramyst in the US by GlaxoSmithKline for the management of chronic obstructive pulmonary disease (COPD). FDA approved on April 27, 2007.

Fluticasone furoate is available as a combination product with vilanterol, a long-acting beta-2 agonist, under the tradename Breo Ellipta. Approved by the FDA in 2013, its use is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.

Structure
Thumb
Synonyms
  • Fluticasonum furoas
  • Furoate de fluticasone
  • Furoato de fluticasona
External IDs
GSK 685698 / GW-685698X / GW685698X
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arnuity ElliptaPowder100 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2016-01-26Not applicableCanada
Arnuity ElliptaPowder200 ug/1Respiratory (inhalation)Glaxosmithkline Inc2014-08-20Not applicableUs
Arnuity ElliptaPowder200 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc2015-12-14Not applicableCanada
Arnuity ElliptaPowder100 ug/1Respiratory (inhalation)Glaxosmithkline Inc2014-08-20Not applicableUs
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
AvamysSpray, metered27.5 mcgNasalGlaxosmithkline Inc2007-10-22Not applicableCanada
AvamysSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-01-11Not applicableEu
VeramystSpray, metered27.5 ug/1NasalLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-05-152017-10-04Us
VeramystSpray, metered27.5 ug/1NasalRemedy Repack2013-06-072017-03-03Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Flonase Sensimist Allergy ReliefSpray, metered27.5 ug/1NasalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2017-02-01Not applicableUs
Flonase Sensimist Allergy ReliefSpray, metered27.5 ug/1NasalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2017-07-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-10-062011-10-09Eu
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-10-062011-10-09Eu
AlisadeSpray, suspension27.5 micrograms/sprayIntrasinalGlaxo Group Limited2008-10-062011-10-09Eu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Breo ElliptaFluticasone furoate (100 mcg) + Vilanterol (25 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc2013-11-29Not applicableCanada
Breo ElliptaFluticasone furoate (200 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)A S Medication Solutions2015-04-302017-06-20Us
Breo ElliptaFluticasone furoate (200 mcg) + Vilanterol (25 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc2015-10-02Not applicableCanada
Breo ElliptaFluticasone furoate (100 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2013-08-26Not applicableUs
Breo ElliptaFluticasone furoate (100 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Remedy Repack2016-04-042017-03-16Us
Breo ElliptaFluticasone furoate (200 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2015-04-30Not applicableUs
Trelegy ElliptaFluticasone furoate (100 ug/1) + Umeclidinium bromide (62.5 ug/1) + Vilanterol Trifenatate (25 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2017-09-18Not applicableUs
Categories
UNII
JS86977WNV
CAS number
397864-44-7
Weight
Average: 538.576
Monoisotopic: 538.163693965
Chemical Formula
C27H29F3O6S
InChI Key
XTULMSXFIHGYFS-VLSRWLAYSA-N
InChI
InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl furan-2-carboxylate
SMILES

Pharmacology

Indication

Fluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.

Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.

Structured Indications
Pharmacodynamics

Fluticasone furoate binds to human glucocorticoid receptor more potently than dexamethasone (29.9-times) and fluticasone propionate (1.7-times). It also is highly retained in respiratory tissue. The significance of this finding is that fluticasone furoate may have a more pronounced and prolonged anti-inflammatory effect, which allows for once-daily dosing. It does not have any effect on the QTc interval. Furthermore, fluticasone furoate was not found to affect the hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma.

Mechanism of action

Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Following intranasal administration of fluticasone furoate, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive first-pass metabolism in the liver and gut, resulting in negligible systemic exposure. Even at the highest recommended intranasal dose of 110 mcg once daily, plasma concentrations were not quantifiable. This is an especially useful feature as it lowers the incidence of adverse events associated with corticosteroid use. If administered using oral solution and intravenous dosing, 30% of the drug is absorbed and rapidly cleared from the plasma. Absolute bioavailability, intranasal route = 0.5%; Absolute bioavailability, oral route = 1.26%; Mean lung absorption time = 7 hours (regardless of formulation);

Volume of distribution

Steady state, IV administration = 608 L

Protein binding

>99% protein bound.

Metabolism

Fluticasone furoate does not undergo cleavage into its two separate components, fluticasone and the furoate moiety. It undergoes extensive hepatic metabolism via CYP3A4. The principal route of metabolism is hydrolysis of the S-fluoromethyl carbothioate function to form the inactive 17β-carboxylic acid metabolite. Studies suggest that enterocytes may be involved in the metabolism of unabsorbed drug.

Route of elimination

Fluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered dose, respectively. Fluticasone furoate is extensively metabolized so very little is excreted unchanged.

Half life

Elimination phase half-life, IV dose = 15.1 hours; Elimination phase half-life, inhaled = 17 - 24 hours;

Clearance

Total plasma clearance = 58.7 L/h

Toxicity

The most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluticasone furoate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluticasone furoate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone furoate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluticasone furoate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluticasone furoate.Approved, Withdrawn
AldesleukinFluticasone furoate may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Fluticasone furoate can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Fluticasone furoate can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Fluticasone furoate can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluticasone furoate.Experimental
AloglutamolThe bioavailability of Fluticasone furoate can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluticasone furoate.Experimental
AluminiumThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone furoate.Approved
AmiodaroneThe metabolism of Fluticasone furoate can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BFluticasone furoate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluticasone furoate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluticasone furoate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone furoate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone furoate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluticasone furoate.Approved, Investigational
AprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Fluticasone furoate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluticasone furoate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone furoate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fluticasone furoate.Experimental
BendroflumethiazideFluticasone furoate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fluticasone furoate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluticasone furoate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluticasone furoate.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone furoate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fluticasone furoate.Experimental
Bismuth SubcitrateThe bioavailability of Fluticasone furoate can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Fluticasone furoate can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Fluticasone furoate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fluticasone furoate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone furoate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluticasone furoate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluticasone furoate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fluticasone furoate.Experimental
BumetanideFluticasone furoate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone furoate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Fluticasone furoate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideFluticasone furoate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Fluticasone furoate can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluticasone furoate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluticasone furoate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluticasone furoate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone furoate.Approved, Investigational
CeritinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluticasone furoate.Approved, Vet Approved
ChlorothiazideFluticasone furoate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneFluticasone furoate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone furoate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Fluticasone furoate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluticasone furoate can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluticasone furoate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Fluticasone furoate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fluticasone furoate can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Fluticasone furoate can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Fluticasone furoate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone furoate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fluticasone furoate can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluticasone furoate.Investigational
CyclopenthiazideFluticasone furoate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluticasone furoate.Investigational
DabrafenibThe serum concentration of Fluticasone furoate can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Fluticasone furoate can be increased when it is combined with Daidzein.Experimental
DanazolFluticasone furoate may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Fluticasone furoate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluticasone furoate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluticasone furoate can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluticasone furoate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluticasone furoate.Approved, Vet Approved
DienestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fluticasone furoate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone furoate.Approved
DihydroergotamineThe metabolism of Fluticasone furoate can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneFluticasone furoate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Fluticasone furoate can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Donepezil.Approved
DoxycyclineThe metabolism of Fluticasone furoate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fluticasone furoate can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluticasone furoate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone furoate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fluticasone furoate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone furoate.Approved
EquolThe serum concentration of Fluticasone furoate can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Fluticasone furoate can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluticasone furoate can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.Approved
Etacrynic acidFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone furoate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fluticasone furoate.Experimental
Ethinyl EstradiolThe serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone furoate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluticasone furoate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone furoate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluticasone furoate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluticasone furoate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluticasone furoate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone furoate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluticasone furoate.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluticasone furoate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fluticasone furoate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluticasone furoate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluticasone furoate.Approved, Withdrawn
FluconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluticasone furoate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fluticasone furoate.Experimental
FluoxymesteroneFluticasone furoate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluticasone furoate.Approved, Investigational
FluvoxamineThe metabolism of Fluticasone furoate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluticasone furoate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluticasone furoate can be increased when combined with Fosphenytoin.Approved
FurosemideFluticasone furoate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluticasone furoate can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluticasone furoate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with GI-5005.Investigational
GLPG-0492Fluticasone furoate may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluticasone furoate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fluticasone furoate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone furoate.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluticasone furoate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone furoate.Approved, Investigational
HydrochlorothiazideFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluticasone furoate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Fluticasone furoate can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluticasone furoate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluticasone furoate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone furoate.Approved
IdelalisibThe serum concentration of Fluticasone furoate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fluticasone furoate can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fluticasone furoate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Fluticasone furoate.Approved
IndapamideFluticasone furoate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Fluticasone furoate can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluticasone furoate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone furoate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone furoate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Fluticasone furoate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone furoate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluticasone furoate.Withdrawn
IsradipineThe metabolism of Fluticasone furoate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluticasone furoate can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluticasone furoate.Experimental
KetoconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone furoate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone furoate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluticasone furoate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone furoate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fluticasone furoate.Experimental
LopinavirThe metabolism of Fluticasone furoate can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone furoate.Approved, Investigational
LovastatinThe metabolism of Fluticasone furoate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone furoate.Approved, Investigational
LuliconazoleThe serum concentration of Fluticasone furoate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fluticasone furoate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluticasone furoate.Approved, Investigational
MagaldrateThe bioavailability of Fluticasone furoate can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone furoate.Approved
Magnesium silicateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluticasone furoate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluticasone furoate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone furoate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone furoate.Approved
MesteroloneFluticasone furoate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone furoate.Investigational, Withdrawn
MethallenestrilThe serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluticasone furoate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone furoate.Approved, Vet Approved
MethyltestosteroneFluticasone furoate may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Metoclopramide.Approved, Investigational
MetolazoneFluticasone furoate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Fluticasone furoate can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone furoate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fluticasone furoate.Experimental
MoxestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone furoate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone furoate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone furoate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone furoate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluticasone furoate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nalidixic Acid.Approved, Investigational
NandroloneFluticasone furoate may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateFluticasone furoate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluticasone furoate.Approved, Vet Approved
NefazodoneThe metabolism of Fluticasone furoate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluticasone furoate.Approved
NetupitantThe serum concentration of Fluticasone furoate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluticasone furoate can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fluticasone furoate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone furoate.Approved
NilotinibThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone furoate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluticasone furoate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Norfloxacin.Approved
OlaparibThe metabolism of Fluticasone furoate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone furoate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluticasone furoate.Vet Approved
OsimertinibThe serum concentration of Fluticasone furoate can be increased when it is combined with Osimertinib.Approved
OxandroloneFluticasone furoate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone furoate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Oxolinic acid.Experimental
OxymetholoneFluticasone furoate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone furoate.Approved, Withdrawn
PalbociclibThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluticasone furoate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fluticasone furoate.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Fluticasone furoate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Fluticasone furoate can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluticasone furoate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone furoate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluticasone furoate.Approved, Investigational
PhenytoinThe metabolism of Fluticasone furoate can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone furoate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pipemidic acid.Experimental
PiretanideFluticasone furoate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone furoate.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone furoate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fluticasone furoate.Experimental
Polyestradiol phosphateThe serum concentration of Fluticasone furoate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluticasone furoate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluticasone furoate.Experimental, Investigational
PrimidoneThe metabolism of Fluticasone furoate can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fluticasone furoate.Experimental
PromestrieneThe serum concentration of Fluticasone furoate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone furoate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fluticasone furoate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fluticasone furoate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone furoate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluticasone furoate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe serum concentration of Fluticasone furoate can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluticasone furoate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate.Approved, Experimental, Investigational
RifabutinThe metabolism of Fluticasone furoate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluticasone furoate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluticasone furoate can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluticasone furoate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone furoate.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone furoate.Approved
SaquinavirThe metabolism of Fluticasone furoate can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Fluticasone furoate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fluticasone furoate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone furoate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluticasone furoate.Investigational
SildenafilThe metabolism of Fluticasone furoate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluticasone furoate can be increased when it is combined with Simeprevir.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Fluticasone furoate can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluticasone furoate.Investigational
St. John's WortThe serum concentration of Fluticasone furoate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololFluticasone furoate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fluticasone furoate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone furoate.Approved
SulfisoxazoleThe metabolism of Fluticasone furoate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluticasone furoate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone furoate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fluticasone furoate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluticasone furoate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluticasone furoate.Approved, Withdrawn
TelithromycinThe metabolism of Fluticasone furoate can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fluticasone furoate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone furoate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluticasone furoate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone furoate.Approved
TestosteroneFluticasone furoate may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateFluticasone furoate may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone furoate.Approved
TiboloneThe serum concentration of Fluticasone furoate can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Fluticasone furoate can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluticasone furoate.Investigational
TocilizumabThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone furoate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone furoate.Approved
TorasemideFluticasone furoate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone furoate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluticasone furoate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluticasone furoate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone furoate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone furoate.Approved
TromethamineThe bioavailability of Fluticasone furoate can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone furoate.Investigational, Withdrawn
VenlafaxineThe metabolism of Fluticasone furoate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fluticasone furoate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFluticasone furoate may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone furoate.Approved, Investigational
ZeranolThe serum concentration of Fluticasone furoate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluticasone furoate.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone furoate.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Adrienne KOVACSNE-MEZEI, Roman Gabriel, Alexandr Jegorov, "POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF." U.S. Patent US20100240629, issued September 23, 2010.

US20100240629
General References
  1. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. [PubMed:23578031]
  2. Tamm M, Richards DH, Beghe B, Fabbri L: Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106 Suppl 1:S9-19. doi: 10.1016/S0954-6111(12)70005-7. [PubMed:23273165]
  3. Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x. [PubMed:23184737]
External Links
KEGG Drug
D06315
PubChem Compound
9854489
PubChem Substance
175427145
ChemSpider
8030195
BindingDB
50354851
ChEBI
74899
ChEMBL
CHEMBL1676
HET
GW6
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluticasone_furoate
ATC Codes
R03AK10 — Vilanterol and fluticasone furoateR01AD12 — Fluticasone furoateR03BA09 — Fluticasone furoate
AHFS Codes
  • 52:08.08 — Corticosteroids
PDB Entries
3cld
FDA label
Download (469 KB)
MSDS
Download (70.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAsthma Bronchial2
1CompletedBasic ScienceAsthma Bronchial1
1CompletedOtherAsthma Bronchial1
1CompletedPreventionAsthma Bronchial / Healthy Volunteers1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Healthy Volunteers1
1CompletedTreatmentAsthma Bronchial / Hepatic Impairment1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2Active Not RecruitingTreatmentAsthma Bronchial1
2CompletedTreatmentAsthma Bronchial11
2CompletedTreatmentOesophagitis, Eosinophilic1
2RecruitingDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentAsthma Bronchial10
3CompletedTreatmentHayfever Allergic Rhinitis Seasonal Rhinitis / Rhinitis, Allergic, Seasonal1
3CompletedTreatmentHayfever / Rhinitis, Allergic, Seasonal / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial2
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial and Seasonal / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive3
3CompletedTreatmentRhinitis1
3CompletedTreatmentRhinitis, Allergic, Perennial2
3CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentRhinitis / Rhinitis, Allergic, Perennial1
3CompletedTreatmentVasomotor Rhinitis2
3RecruitingTreatmentAsthma Bronchial1
4CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)2
4CompletedBasic ScienceChildhood Obstructive Sleep Apnea Syndrome (OSAS)1
4CompletedTreatmentAllergic Conjunctivitis to Tree Pollen or Grass Pollen1
4CompletedTreatmentAllergic Rhinitis (AR)2
4CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)2
4CompletedTreatmentRhinitis, Allergic, Seasonal2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4RecruitingTreatmentAsthma Bronchial2
4Unknown StatusTreatmentPatients With Nasal Polyps1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
Not AvailableCompletedNot AvailableCognition / Driving Ability / Seasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableTerminatedTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Spray, suspensionIntrasinal27.5 micrograms/spray
PowderOral; Respiratory (inhalation)100 mcg
PowderOral; Respiratory (inhalation)200 mcg
PowderRespiratory (inhalation)100 ug/1
PowderRespiratory (inhalation)200 ug/1
Spray, meteredNasal27.5 mcg
PowderRespiratory (inhalation)
Spray, meteredNasal27.5 ug/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5873360Yes1996-08-232016-08-23Us
US6858596No2001-08-032021-08-03Us
US7101866No2001-08-032021-08-03Us
US7541350No2001-08-032021-08-03Us
US8347879No2008-07-152028-07-15Us
US8752543No2006-04-052026-04-05Us
US8062264No2006-04-052026-04-05Us
US8147461No2008-10-152028-10-15Us
US7439393No2002-09-112022-09-11Us
US6759398No2001-08-032021-08-03Us
USRE44874No2003-03-232023-03-23Us
US6537983No2001-08-032021-08-03Us
US8511304No2007-06-142027-06-14Us
US7629335No2001-08-032021-08-03Us
US8161968No2008-02-052028-02-05Us
US8746242No2010-10-112030-10-11Us
US8113199No2007-10-232027-10-23Us
US7776895No2002-09-112022-09-11Us
US8534281No2009-08-102029-08-10Us
US6878698No2001-08-032021-08-03Us
US8201556No2009-02-052029-02-05Us
US9320862No2004-11-062024-11-06Us
US9333310No2007-10-022027-10-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
pKa6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0434 mg/mLALOGPS
logP3.73ALOGPS
logP4.13ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity130.08 m3·mol-1ChemAxon
Polarizability51.55 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9666
Caco-2 permeable-0.5222
P-glycoprotein substrateSubstrate0.7675
P-glycoprotein inhibitor IInhibitor0.784
P-glycoprotein inhibitor IIInhibitor0.604
Renal organic cation transporterNon-inhibitor0.8329
CYP450 2C9 substrateNon-substrate0.8023
CYP450 2D6 substrateNon-substrate0.8893
CYP450 3A4 substrateSubstrate0.7205
CYP450 1A2 substrateNon-inhibitor0.6493
CYP450 2C9 inhibitorNon-inhibitor0.7288
CYP450 2D6 inhibitorNon-inhibitor0.8305
CYP450 2C19 inhibitorNon-inhibitor0.6388
CYP450 3A4 inhibitorInhibitor0.9211
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.69
Ames testNon AMES toxic0.747
CarcinogenicityNon-carcinogens0.9079
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6232 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.566
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Furoic acid esters / Heteroaromatic compounds / Thioesters / Secondary alcohols / Carbothioic S-esters
show 11 more
Substituents
Steroid ester / Androgen-skeleton / Androstane-skeleton / Hydroxysteroid / Halo-steroid / 6-halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
thioester, 11beta-hydroxy steroid, steroid ester, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid, 2-furoate ester (CHEBI:74899)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM: Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008 Nov;36(11):2337-44. doi: 10.1124/dmd.108.022137. Epub 2008 Aug 11. [PubMed:18694910]

Drug created on June 16, 2013 17:03 / Updated on November 19, 2017 20:34